PRQR · ProQR Therapeutics N.V.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-31 | de Boer Daniel Anton |
Director, Chief Executive Officer |
Buy↑
|
Ordinary Shares
|
200,000 |
| 2026-07-17 | Filius Bart |
Director |
Buy↑
|
Ordinary Shares
|
150,000 |
| 2026-07-09 | de Boer Daniel Anton |
Director, Chief Executive Officer |
Buy↑
|
Ordinary Shares
|
150,000 |
| 2026-07-07 | de Boer Daniel Anton |
Director, Chief Executive Officer |
Buy↑
|
Ordinary Shares
|
150,000 |
| 2026-06-26 | Filius Bart |
Director |
Buy↑
|
Ordinary Shares
|
150,000 |
| 2026-06-02 | Hinsch Gylvin Lykke |
Director |
Award↑
Filing footnotes — Share Option (Right to Buy) (Direct)
The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy. 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Share Option (Right to Buy)
|
14,595 |